Immunovant(IMVT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 • Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402 • Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiatio ...